# Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)

> **NCT04252963** · PHASE4 · UNKNOWN · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 346 (estimated)

## Conditions studied

- Acute Upper Respiratory Infection
- Acute Bronchitis

## Interventions

- **DRUG:** MUCOLASE tablet (streptokinase • streptodornase)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04252963
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-02
- **Primary completion:** 2021-02
- **Final completion:** 2021-05
- **Target enrollment:** 346 (ESTIMATED)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252963, "Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04252963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*